perhexiline has been researched along with cardiovascular agents in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.79) | 18.7374 |
| 1990's | 10 (17.86) | 18.2507 |
| 2000's | 23 (41.07) | 29.6817 |
| 2010's | 19 (33.93) | 24.3611 |
| 2020's | 3 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Funck-Brentano, C | 1 |
| Decker, N; Leclerc, G; Schwartz, J | 1 |
| Horowitz, JD; Kennedy, JA; Unger, SA | 1 |
| Pillans, PI | 1 |
| Horowitz, JD; Northey, DL; Stewart, S; Voss, DW | 1 |
| Gabb, GM; Siebert, WJ; Wing, LM | 1 |
| Horowitz, JD; Robinson, MA; Unger, SA | 1 |
| Grgurinovich, N | 1 |
| Chirkov, YY; Chirkova, LP; Horowitz, JD; Kennedy, JA; Murphy, GA; Willoughby, SR | 1 |
| Breit, SN; Bursill, JA; Campbell, TJ; Qiu, MR; Singleton, CB; Tie, H; Valenzuela, SM; Walker, BD; Wyse, KR | 1 |
| Morris, RG; Sallustio, BC | 1 |
| Morris, RG; Sallustio, BC; Westley, IS | 1 |
| Chirkov, YY; Holmes, AS; Horowitz, JD; Stewart, S; Willoughby, SR | 1 |
| Frenneaux, M | 1 |
| Chirkov, YY; Holmes, AS; Horowitz, JD; Kennedy, JA; Stewart, S; Willoughby, SR | 1 |
| Killalea, SM; Krum, H | 1 |
| Coller, JK; Davies, BJ; Gillis, D; Horowitz, JD; James, HM; Morris, RG; Sallustio, BC; Somogyi, AA | 1 |
| Frenneaux, M; Horowitz, J; Lee, L | 1 |
| Beck, O; Hjemdahl, P; Morris, RG; Sallustio, BC; Stephanson, N | 1 |
| Chandy, S; Horowitz, JD; Morris, R; Philpott, A | 1 |
| Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L | 1 |
| Begg, EJ | 1 |
| Beck-Oldach, K; Horowitz, JD; Kennedy, JA; McFadden-Lewis, K; Murphy, GA; Wong, YW; Zhang, Y | 1 |
| Inglis, S; Stewart, S | 1 |
| Coller, JK; Davies, BJ; Horowitz, JD; James, HM; Sallustio, BC; Somogyi, AA | 1 |
| Abozguia, K; Clarke, K; Frenneaux, M; Lee, L | 1 |
| Coller, JK; Davies, BJ; Milne, RW; Sallustio, BC; Somogyi, AA | 1 |
| Ashley, EA; deGoma, EM; Fowler, MB; Vagelos, RH | 1 |
| Coller, JK; Davies, BJ; Herbert, MK; Horowitz, JD; Inglis, SC; James, HM; Milne, RW; Morris, RG; Sallustio, BC; Somogyi, AA | 1 |
| Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F | 1 |
| Ashrafian, H; Frenneaux, MP; Williams, L | 1 |
| Arioli, F; Bassanelli, G; Fragasso, G; Margonato, A; Salerno, A; Spoladore, R | 1 |
| Abozguia, K; Ahmed, I; Choudhury, A; Davies, C; Frenneaux, M; Horowitz, J; Naidoo, U; Phan, TT; Shivu, GN; Yousef, Z | 1 |
| Drake-Holland, AJ; Noble, MI | 1 |
| Balgi, AD; Donohue, E; Fonseca, BD; Lajoie, P; Nabi, IR; Proud, CG; Roberge, M; Tsang, TC | 1 |
| Bansal, M; Chan, J; Horowitz, J; Leano, R; Marwick, TH; Pillans, P | 1 |
| Chirkov, YY; Horowitz, JD; Kennedy, JA; Sverdlov, AL | 1 |
| Chirkov, YY; Horowitz, JD | 1 |
| Averbuj, P; Chik, W; Horowitz, JD; Ling, LH; Morris, RG; Ngo, DT; Pati, PK; Sallustio, BC; Sverdlov, AL | 1 |
| Abozguia, K; Beadle, RM; Frenneaux, MP; Leon, FL; Patel, K; Wagenmakers, A; Williams, LK; Yousef, Z | 1 |
| Ao, Z; Bradley, BT; Daniels, E; Douglas, SA; Gatto, GJ; Goodman, KB; Goserud, MT; Harpel, MR; Johns, DG; Kearse, MG; Morales, CR; Zhou, M | 1 |
| Drozdov, I; Dwyer, J; Edwards, LM; Griffiths, J; Langley, SR; Madhu, B; Mayr, M; Mayr, U; Nabeebaccus, A; Shah, AM; Xing, Q; Yin, X | 1 |
| Licari, G; Milne, RW; Sallustio, BC; Somogyi, AA | 1 |
| Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S | 1 |
| Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z | 1 |
| Amaral, N; Okonko, DO | 1 |
| Choi, BY; Chong, CR; Horowitz, JD; Phuong, H; Raman, B | 1 |
| Chong, CR; Drury, NE; Frenneaux, MP; Horowitz, JD; Licari, G; Pagano, D; Sallustio, BC | 1 |
| Frenneaux, MP; Gollop, ND; Loudon, BL; Madhani, M; Noordali, H | 1 |
| Chong, CR; Horowitz, JD; Sallustio, B | 1 |
| Bannister, ML; George, CH; Mitchell, AN; Preece, R; Yousef, Z | 1 |
| Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M | 1 |
| Frenneaux, MP; Grant, DM; Greig, IR; Madhani, M; Noordali, H; Sani, M; Tseng, CC; Zanda, M | 1 |
| Chen, S; Guo, L; Guo, X; Li, D; Ning, B; Ren, Z; Seo, JE | 1 |
| Ananthakrishna, R; Binda, G; Foote, J; Horowitz, JD; Lee, SL; Mangoni, AA; Sallustio, BC; Selvanayagam, JB; Semsarian, C; Woodman, R | 1 |
| Dhakal, B; Drew, P; Fenix, K; Maddern, G; Price, T; Smith, E; Tomita, Y | 1 |
16 review(s) available for perhexiline and cardiovascular agents
| Article | Year |
|---|---|
[Genetic polymorphism of the metabolism of drugs used in cardiac diseases].
Topics: Acetyltransferases; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cardiovascular Agents; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Perhexiline; Pharmacogenetics; Phenotype; Polymorphism, Genetic | 1991 |
Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
Topics: Angina Pectoris; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Perhexiline; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic | 2001 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Enzyme Inhibitors; Epoxy Compounds; Glucose; Humans; Hypoglycemic Agents; Insulin; Myocardial Ischemia; Myocardium; Perhexiline; Piperazines; Potassium; Ranolazine; Trimetazidine | 2004 |
Individualized drug and dose: the clinical pharmacologist's calling or curse?
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Drug Monitoring; Genotype; Humans; Liver; Milk, Human; Models, Biological; Perhexiline; Pharmaceutical Preparations; Pharmacogenetics; Pharmacokinetics; Pharmacology, Clinical | 2005 |
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Topics: Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Energy Metabolism; Epoxy Compounds; Fatty Acids, Nonesterified; Glycine; Heart; Humans; Myocardium; Oxygen; Perhexiline; Piperazines; Ranolazine; Trimetazidine | 2006 |
Emerging therapies for the management of decompensated heart failure: from bench to bedside.
Topics: Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Cardiac Myosins; Cardiotonic Agents; Cardiovascular Agents; Etiocholanolone; Heart Failure; Humans; Natriuretic Agents; Peptide Fragments; Perhexiline; Purinergic P1 Receptor Antagonists; Sodium-Potassium-Exchanging ATPase | 2006 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Hydrazones; Natriuretic Peptide, Brain; Perhexiline; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium-Potassium-Exchanging ATPase; Syndrome; Vasodilator Agents | 2008 |
Metabolic therapy of heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Fatty Acids, Nonesterified; Heart Failure; Humans; Myocardium; Perhexiline; Trimetazidine | 2008 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardial Reperfusion; Myocardium; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2010 |
Metabolic abnormalities of the heart in type II diabetes.
Topics: Antioxidants; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Fatty Acids; Glucose; Humans; Mitochondria, Heart; Myocardium; Organophosphorus Compounds; Oxidative Phosphorylation; Oxidative Stress; Perhexiline; Ranolazine; Trimetazidine; Ubiquinone | 2015 |
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm.
Topics: Cardiovascular Agents; Heart Failure; Humans; Nitrites; Perhexiline | 2016 |
Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
Topics: Angina Pectoris; Animals; Cardiovascular Agents; Fatty Acids; Glucose; Humans; Mitochondria; Myocardium; Perhexiline | 2016 |
Pleiotropic mechanisms of action of perhexiline in heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Design; Heart Failure; Humans; Molecular Targeted Therapy; Patents as Topic; Perhexiline; Reactive Oxygen Species; Tissue Distribution | 2016 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine | 2016 |
Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects.
Topics: Cardiovascular Agents; Fatty Acids; Humans; Mitochondria; Neoplasms; Perhexiline | 2023 |
10 trial(s) available for perhexiline and cardiovascular agents
| Article | Year |
|---|---|
Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Calcium Channel Blockers; Cardiovascular Agents; Dizziness; Drug Monitoring; Female; Humans; Male; Middle Aged; Nausea; Perhexiline; Vasodilator Agents | 1996 |
Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide.
Topics: Aged; Angina Pectoris; Blood Platelets; Cardiovascular Agents; Coronary Disease; Cyclic GMP; Female; Humans; Male; Neutrophils; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Perhexiline; Platelet Aggregation; Superoxides | 2002 |
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Female; Humans; Male; Perhexiline | 2004 |
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Echocardiography, Stress; Fatty Acids; Female; Glucose; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardium; Oxygen Consumption; Perhexiline; Quality of Life; Stroke Volume; Treatment Outcome | 2005 |
Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction.
Topics: Aged; Cardiotonic Agents; Cardiovascular Agents; Dobutamine; Echocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Perhexiline; Placebos; Treatment Failure; Ventricular Dysfunction, Left; Ventricular Function, Left | 2010 |
Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.
Topics: Adenosine Triphosphate; Cardiac Catheterization; Cardiomyopathy, Dilated; Cardiovascular Agents; Double-Blind Method; Drug Monitoring; Echocardiography, Doppler; Energy Metabolism; Heart Failure; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Myocardium; Perhexiline; Phosphocreatine; Placebo Effect; Prospective Studies; Recovery of Function; Research Design; Stroke Volume; Time Factors; Treatment Outcome; United Kingdom; Ventricular Function, Left | 2011 |
Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
Topics: Cardiovascular Agents; Clinical Protocols; Double-Blind Method; Heart Failure; Humans; Outcome Assessment, Health Care; Perhexiline; Stroke Volume; Syndrome | 2014 |
Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiovascular Agents; Double-Blind Method; Echocardiography; Energy Metabolism; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Myocardium; Perhexiline; Retrospective Studies; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.
Topics: Administration, Oral; Aged; Cardiovascular Agents; Heart Atria; Heart Ventricles; Humans; Middle Aged; Myocardium; Perhexiline; Stereoisomerism; Tissue Distribution | 2015 |
Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial).
Topics: Adult; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Double-Blind Method; Echocardiography; Female; Humans; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Perhexiline; Prospective Studies | 2021 |
30 other study(ies) available for perhexiline and cardiovascular agents
| Article | Year |
|---|---|
Synthesis and cardiovascular activity of a new series of cyclohexylaralkylamine derivatives related to perhexiline.
Topics: Adrenergic alpha-Antagonists; Animals; Calcium Channel Blockers; Cardiovascular Agents; Chemical Phenomena; Chemistry; Coronary Circulation; Dogs; Female; Male; Perhexiline; Piperidines; Rats; Swine | 1982 |
Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Male; Mitochondria, Heart; Mitochondria, Liver; Perhexiline; Rats; Rats, Sprague-Dawley; Subtilisins | 1996 |
Drug associated hepatic reactions in New Zealand: 21 years experience.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anesthetics, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Calcium Channel Blockers; Cardiovascular Agents; Cause of Death; Clavulanic Acids; Diclofenac; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Erythromycin; Female; Floxacillin; Halothane; Humans; Liver; Male; Middle Aged; New Zealand; Penicillins; Perhexiline; Steroids | 1996 |
Perhexiline--stable plasma concentrations with formulation change.
Topics: Aged; Angina Pectoris; Biological Availability; Cardiovascular Agents; Drug Compounding; Female; Humans; Male; Middle Aged; Perhexiline; Therapeutic Equivalency | 1996 |
Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Cardiovascular Agents; Female; Humans; Male; Perhexiline; Treatment Outcome | 1997 |
Method for the analysis of perhexiline and its hydroxy metabolite in plasma using high-performance liquid chromatography with precolumn derivatization.
Topics: Cardiovascular Agents; Chromatography, High Pressure Liquid; Circadian Rhythm; Drug Interactions; Ethylamines; Humans; Hydroxides; Linear Models; Perhexiline; Reproducibility of Results | 1997 |
Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
Topics: Adult; Aged; Amiodarone; Blood Platelets; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Case-Control Studies; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Female; Humans; Male; Middle Aged; Perhexiline; Platelet Aggregation; Trimetazidine; Vasodilator Agents | 1998 |
Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate.
Topics: Algorithms; Animals; Anti-Arrhythmia Agents; Cardiovascular Agents; Cation Transport Proteins; CHO Cells; Cricetinae; Electric Stimulation; Ether-A-Go-Go Potassium Channels; In Vitro Techniques; Membrane Potentials; Oocytes; Patch-Clamp Techniques; Perhexiline; Piperidines; Potassium Channels; Potassium Channels, Voltage-Gated; Pyridines; Xenopus laevis | 1999 |
Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
Topics: Angina Pectoris; Australia; Cardiovascular Agents; Chromatography, Gas; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Laboratories; Perhexiline; Quality Control; Reproducibility of Results | 1999 |
Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
Topics: Angina Pectoris; Biological Availability; Cardiovascular Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Humans; Metabolic Clearance Rate; Perhexiline; Phenotype; Retrospective Studies; Sensitivity and Specificity | 2002 |
Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitric Oxide; Nitroprusside; Perhexiline; Platelet Aggregation; Platelet Aggregation Inhibitors; Severity of Illness Index; Statistics as Topic; Stroke Volume; Ventricular Function, Left | 2002 |
New tricks for an old drug.
Topics: Cardiovascular Agents; Humans; Nitric Oxide; Perhexiline; Platelet Aggregation | 2002 |
Determination of perhexiline and hydroxyperhexiline in plasma by liquid chromatography-mass spectrometry.
Topics: Cardiovascular Agents; Chromatography, High Pressure Liquid; Humans; Isomerism; Mass Spectrometry; Perhexiline; Reference Standards | 2004 |
Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
Topics: Adult; Cardiovascular Agents; Coronary Disease; Drug Administration Schedule; Drug Overdose; Female; Humans; Male; Middle Aged; Perhexiline; Self Medication | 2004 |
Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation.
Topics: Angina Pectoris; Animals; Animals, Newborn; Aorta, Thoracic; Aortic Valve; Cardiovascular Agents; Cell Membrane; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Free Radical Scavengers; Humans; In Vitro Techniques; Luminescent Measurements; Male; N-Formylmethionine Leucyl-Phenylalanine; NADP; NADPH Oxidases; Neutrophils; Perhexiline; Rats; Rats, Wistar; Superoxides; Swine; Tetradecanoylphorbol Acetate | 2006 |
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
Topics: Aged; Aged, 80 and over; Alleles; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Gene Frequency; Genotype; Humans; Middle Aged; Myocardial Ischemia; Perhexiline; Polymorphism, Single Nucleotide | 2006 |
CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Topics: Antibodies, Monoclonal; Cardiovascular Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Microsomes, Liver; Oxidation-Reduction; Perhexiline; Recombinant Proteins; Stereoisomerism | 2007 |
Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Topics: Biological Availability; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Genotype; Humans; Metabolic Clearance Rate; Myocardial Ischemia; Perhexiline; Phenotype; Polymorphism, Genetic; Prospective Studies; Retrospective Studies; Sensitivity and Specificity; Stereoisomerism | 2007 |
The pathophysiology of heart failure: a tale of two old paradigms revisited.
Topics: Cardiovascular Agents; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Heart Failure; Humans; Metabolic Networks and Pathways; Perhexiline; Trimetazidine; Vasodilator Agents | 2008 |
Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope.
Topics: Aged; Analysis of Variance; Angina Pectoris; Cardiovascular Agents; Confidence Intervals; Drug Monitoring; Female; Health Status Indicators; Humans; Logistic Models; Male; Odds Ratio; Perhexiline; Proportional Hazards Models; Prospective Studies; Time Factors; Treatment Failure; Vasodilator Agents | 2009 |
Lack of effect of perhexiline in ischaemic heart failure.
Topics: Cardiovascular Agents; Humans; Myocardial Ischemia; Perhexiline; Treatment Failure | 2010 |
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
Topics: Acetophenones; Amiodarone; Antinematodal Agents; Automation; Autophagy; Benzopyrans; Cardiovascular Agents; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Mechanistic Target of Rapamycin Complex 1; Models, Chemical; Multiprotein Complexes; Niclosamide; Nutritional Sciences; Perhexiline; Proteins; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors | 2009 |
Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation.
Topics: Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Energy Metabolism; Exercise Tolerance; Humans; Myocardium; Perhexiline | 2010 |
Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
Topics: Aged; Aged, 80 and over; Aging; Angina Pectoris; Body Weight; Cardiovascular Agents; Creatinine; Humans; Middle Aged; Perhexiline; Renal Insufficiency; Retrospective Studies; Ventricular Dysfunction, Left | 2011 |
NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation.
Topics: Base Sequence; Benzoxazoles; Cardiovascular Agents; Cells, Cultured; Enzyme Inhibitors; Humans; Membrane Glycoproteins; Molecular Sequence Data; NADPH Oxidase 2; NADPH Oxidases; Neutrophils; Perhexiline; Protein Kinase C; Protein Kinase C beta; Reactive Oxygen Species; Suramin; Triazoles | 2013 |
Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome.
Topics: Animals; Cardiovascular Agents; Cluster Analysis; Computer Simulation; Heart; Male; Metabolome; Metabolomics; Mice; Models, Biological; Myocardium; Perhexiline; Proteome; Proteomics | 2013 |
Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats.
Topics: Alcohol Oxidoreductases; Animals; Cardiovascular Agents; Cytochrome P450 Family 2; Female; Liver; Models, Animal; Perhexiline; Rats, Sprague-Dawley | 2015 |
Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug Monitoring; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Male; Myocardial Ischemia; Perhexiline; Survival Rate; Time Factors | 2016 |
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
Topics: Animals; Cardiovascular Agents; Cytochrome P-450 CYP2D6; Halogenation; Heart; Humans; Male; Mice, Inbred BALB C; Myocardial Contraction; Myocardium; Perhexiline | 2017 |
Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline.
Topics: Apoptosis; Cardiovascular Agents; Cell Line; Chemical and Drug Induced Liver Injury; Hepatocytes; Humans; Membrane Potential, Mitochondrial; Mitochondria; Perhexiline; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2020 |